Pfizer Fights Celebrex Plaintiffs' Bid To Bar Experts

Law360, New York (August 14, 2007, 12:00 AM EDT) -- Firing the latest salvo in a dispute over proposed testimony, Pfizer Inc. has opposed a bid by plaintiffs in the multidistrict product liability litigation over its anti-inflammatory drug Celebrex to bar certain experts' opinions.

The drug company said in court documents filed Monday in the U.S. District Court for the Northern District of California that the court should deny the plaintiffs' July 20 motion to bar the testimony of four doctors Pfizer has designated as expert witnesses in the case, arguing that the plaintiffs have focused...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.